Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment

Nintedanib is an intracellular inhibitor of tyrosine kinases used in the treatment of non–small cell lung cancer and idiopathic pulmonary fibrosis (IPF). This phase 1 open‐label study investigated the influence of mild and moderate hepatic impairment on the pharmacokinetics (PK), safety, and tolerab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Pharmacol
Main Authors: Marzin, Kristell, Kretschmar, Gunther, Luedtke, Doreen, Kraemer, Sandrine, Kuelzer, Raimund, Schlenker‐Herceg, Rozsa, Schmid, Ulrike, Schnell, David, Dallinger, Claudia
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Special Populations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5836871/
https://ncbi.nlm.nih.gov/pubmed/29106740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1025
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados